ArticleFrontiers in medical technology2025
The treatment of challenging visceral and peripheral arterial aneurysms with flow diversion-a German multicentric observational study.
Article in Frontiers in medical technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Endovascular treatment of visceral and peripheral aneurysms has become the modality of choice over the past few decades. A variety of different techniques are being applied, including deconstructive approaches, such as parent vessel occlusion with coils or liquid embolic agents, and reconstructive approaches, such as stent grafting, stent-assisted coiling, or balloon-assisted coiling. Reconstruction is preferred over vessel or segmental sacrifice due to the risk of ischemia in the dependent territory. However, conventional reconstructive techniques fail, possibly due to the tortuosity of the parent artery or involvement of arterial bifurcations. Flow diversion, a comparatively novel method using densely braided stents, has become well established as a therapeutic option for the treatment of uncoilable or failed aneurysms in cerebral circulation because flow diverter stents can be implanted in highly tortuous vessels and can also be used to treat bifurcation aneurysms without causing occlusion of non-collateralized side branches under sufficient inhibition of platelet function. A few reports have been published on the use of flow diverter stents for the treatment of aneurysms in visceral or peripheral circulation, but systematic studies are lacking. The purpose of this multicenter study is to summarize the experience of different vascular centers that have utilized flow diversion techniques in peripheral vasculature. Materials and methods: This multicentric retrospective analysis includes data from 10 vascular centers on treatments performed between 2022 and 2025. Aside from the safety and feasibility of the approach, procedural aspects, antiplatelet medication, follow-up results, and complications were investigated in a retrospective manner. Results: A total of 36 patients (22 female, with a mean age of 59.2 years, ranging between 36 and 80 years), one with two aneurysms, were treated in the following arterial territories with decreasing frequency: splenic artery ( Conclusion: Our multicenter observational study demonstrated the excellent safety and efficacy of flow diversion as an alternative treatment modality for visceral and peripheral aneurysms. The complication rates were low, and all complications were related to insufficient inhibition of platelet function during the intervention or in the early postinterventional phase, which can be addressed by platelet function testing prior to the interventions, followed by tailored antiplatelet therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.